Emcure Pharmaceuticals develops and markets generics, branded generics, biosimilars and complex injectables across India, Europe, Canada and emerging markets, and heads into its September quarter with the domestic pharma market growing at its fastest pace in six quarters. The print will speak to whether the company sustains its higher-end FY27 revenue growth guidance and holds the 70-100 bps EBITDA margin expansion path even as gross margin stays under mix pressure and net debt builds toward the guided ~Rs. 1,450 Cr.
| Results date | November 03, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 2,580.40 Cr (+22.8% YoY) |
| Previous quarter PAT | Rs. 292.50 Cr (+36.2% YoY) |
| Previous quarter EBITDA margin | 19.7% (+50 bps YoY) |
| Net debt (latest quarter) | Rs. 1,103 Cr at Jun 30, 2026 |
| Market cap | Rs. 35,411.26 Cr |
| CMP | Rs. 1,865.0 |
The board of Emcure Pharmaceuticals will meet on November 3, 2026, to approve unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The trading window remains closed from October 1 to November 5, 2026.
An earnings call is scheduled for November 3, 2026, at 4:00 pm IST via Zoom, with the transcript to be filed within 5 working days.
The September quarter will test whether Emcure's FY27 delivery-year thesis holds: management has revised its comfort to the higher end of the low-to-mid-teens revenue growth guidance after Q1 FY27 revenue grew 22.8% YoY to Rs. 2,580 Cr, with PAT up 36.2% to Rs. 292 Cr. The domestic backdrop is supportive — the Indian pharma market grew 12% by value in the September quarter per Pharmarack, accelerating from 11.3% in the June quarter, with September volume growth of 3.5% marking a two-year high — while the rupee's slide past 95/USD (from 87.91 a year earlier) offers a translation tailwind to the 58% international revenue base. The margin bridge is the key test: gross margin fell 340 bps YoY to 58.4% in Q1 on Europe/ARV/B2B mix against a ~59% FY27 target, and management has guided EBITDA margin expansion of 70-100 bps for FY27 after Q1 delivered +50 bps, with OAD entering the growth base from Q2. On the balance sheet, net debt stood at Rs. 1,103 Cr at Jun 30, 2026, and management guided a Rs. 450-500 Cr build in Q2 from Mantra and Gennova payments to ~Rs. 1,450 Cr by quarter-end, en route to a net cash position by end-FY28. The call is also expected to cover the Zuventus-Emcutix merger (NCLT Mumbai approval pending), Poviztra's ramp after the April 2026 price cut and MASH indication, Amphotericin B's 'significant contribution in FY27', Lenacapavir registration targeted in FY27, and updates on the Rs. 57.74 Cr income-tax demand and the 51.09% public-institutional vote against the MD & CEO's re-appointment.
Guidance scorecard to test on the call: Management reiterated FY27 guidance at the Q1 call; here is where each item stands.
Strategic initiative updates to expect
Risk follow-ups
Domestic growth and metric watch
Management attributes the gross margin decline — down 340 bps YoY to 58.4% in Q1 FY27 — to business mix from the Sanofi OAD portfolio, Poviztra, Europe and ARV/B2B models, which carry lower gross margins but are 'more accretive at the EBITDA level'. FY27 gross margin is expected to settle around 59%.
Management has guided for a net cash position by end-FY28, with net debt zero by December 2028. Net debt stood at Rs. 1,103 Cr at Jun 30, 2026, and is guided to rise by Rs. 450-500 Cr in Q2 FY27 to ~Rs. 1,450 Cr on Mantra and Gennova payments.
Emcure holds exclusive India rights to Novo Nordisk's Poviztra (semaglutide 2.4 mg for weight loss), launched in late December 2025, with a MASH indication recently added. Management declined to quantify the opportunity against the Rs. 200 Cr Sanofi in-licensed portfolio, citing a 250-350 mn obese population, but expects 'reasonable growth in FY27' after the April 2026 price cut.
An aggregate penalty of Rs. 57,73,96,732 (Rs. 57.74 Cr) was imposed by the Deputy Commissioner of Income Tax, Central Circle 2(1), Pune, covering FY2014-15 to FY2020-21. The company is evaluating legal remedies, including an appeal before the Appellate Authority.
Management has guided domestic organic growth at par or faster than the industry's 8-9% for FY27, with Q2 stated to be 'in line with guidance' and H2 faster than industry. The Indian pharma market itself grew 12% by value in the September quarter, up from 11.3% in the June quarter.